ImmunityBio, Inc. IBRX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s other income, net (note 6)?
- ImmunityBio, Inc. (IBRX) reported other income, net (note 6) of -$5.92M in Q1 2026.
- How has ImmunityBio, Inc.'s other income, net (note 6) changed year-over-year?
- ImmunityBio, Inc.'s other income, net (note 6) decreased by 14331.7% year-over-year, from -$41K to -$5.92M.
- What is the long-term trend for ImmunityBio, Inc.'s other income, net (note 6)?
- Over 2 years (2022 to 2025), ImmunityBio, Inc.'s other income, net (note 6) has grown at a 71.9% compound annual growth rate (CAGR), from -$736K to -$2.17M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.